Efficacy and safety of garadacimab in patients with severe COVID-19
A. Papi (Ferrara, Italy), R. Stapleton (Burlington, United States), P. Shore (Pennsylvania, United States), M. Bica (Marburg, Germany), Y. Chen (Pennsylvania, United States), M. Larbig (Bern, Switzerland), T. Welte (Hannover, Germany)
Source: International Congress 2022 – COVID treatments
Session: COVID treatments
Session type: Thematic Poster
Number: 2597
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Papi (Ferrara, Italy), R. Stapleton (Burlington, United States), P. Shore (Pennsylvania, United States), M. Bica (Marburg, Germany), Y. Chen (Pennsylvania, United States), M. Larbig (Bern, Switzerland), T. Welte (Hannover, Germany). Efficacy and safety of garadacimab in patients with severe COVID-19. 2597
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|